Lineage Cell Therapeutics (LCTX) EBT Margin Growth (3y) (2013 - 2026)
Lineage Cell Therapeutics (LCTX) EBT Margin Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -484.00 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 132.00 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -674,462.00 |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8,006.00 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 71,157.00 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -5,319.00 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 9,980.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 31,363.00 |
| 10 | Lineage Cell Therapeutics | 270.61 Mn | 212.77 Mn | 1.07 Mn | -129,910.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -129,910.00 |
| Mar 31, 2026 | -86,038.00 |
| Dec 31, 2025 | 22,845.00 |
| Sep 30, 2025 | -32,605.00 |
| Jun 30, 2025 | -66,605.00 |
| Mar 31, 2025 | -31,796.00 |
| Dec 31, 2024 | -5,730.00 |
| Sep 30, 2024 | 31,028.00 |
| Jun 30, 2024 | 55,971.00 |
| Mar 31, 2024 | -8,382.00 |
| Dec 31, 2023 | -50,295.00 |
| Sep 30, 2023 | 81,782.00 |
| Jun 30, 2023 | 153,038.00 |
| Mar 31, 2023 | 137,955.00 |
| Dec 31, 2022 | 9,808.00 |
| Sep 30, 2022 | 290,152.00 |
| Jun 30, 2022 | 386,902.00 |
| Mar 31, 2022 | -389,751.00 |
| Dec 31, 2021 | 592,419.00 |
| Sep 30, 2021 | -716,607.00 |